Enanta Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-81.9M | $-116.0M | $-133.8M | $-121.8M | $-79.0M | $-36.2M | $46.4M | $72.0M |
| Depreciation & Amortization | $4.6M | $2.3M | $2.4M | $3.0M | $3.3M | $3.6M | $3.3M | $2.5M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $18.6M | $26.8M | $28.2M | $27.0M | $21.0M | $19.6M | $19.2M | $15.8M |
| Net Cash from Operating Activities | $-19.3M | $-78.8M | $-103.2M | $-84.8M | $-70.0M | $7.1M | $71.4M | $29.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $12.9M | $17.9M | $9.1M | $2.1M | $750.0K | $1.4M | $5.4M | $3.0M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $40.3M | $58.2M | $-53.6M | $54.9M | $37.0M | $19.8M | $-86.7M | $-35.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-26.6M | $-27.6M | $198.1M | $20.0M | $3.1M | $9.0M | $2.6M | $4.4M |
| Net Change in Cash | $-5.5M | $-48.2M | $41.4M | $-9.9M | $-29.9M | $35.9M | $-12.7M | $-1.8M |
| Free Cash Flow | $-32.2M | $-96.7M | $-112.2M | $-86.9M | $-70.7M | $5.6M | $66.0M | $26.2M |